Trial Profile

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirexatamab (Primary) ; Cisplatin; Gemcitabine
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
Focus Adverse reactions
Sponsors HealthCare Pharmaceuticals Inc; Leap Therapeutics

02 Sep 2020 Results published in the Clinical Cancer Research
14 Dec 2018 According to a Leap Therapeutics media release, data from this trial was presented today at the European Society for Molecular Oncology (ESMO) Immuno-Oncology Congress 2018.
14 Dec 2018 Results presented in a Leap Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com